Related Experiment Videos
Recombinant immunotoxins
I Pastan1, L H Pai, U Brinkmann
1Laboratory of Molecular Biology, DCBDC, National Cancer Institute, NIH, Bethesda, MD, USA.
Breast Cancer Research and Treatment
|January 1, 1996
Abstract:
Pseudomonas exotoxin has been genetically modified so that it targets cancer cells. This was accomplished by deleting its cell binding domain and replacing it with Fv fragments of antibodies that react with breast, colon, and other cancers. Several recombinant immunotoxins are now in clinical trials.
Insights
Genetically modified Pseudomonas exotoxin targets cancer cells by replacing its binding domain with cancer-specific antibody fragments. These novel recombinant immunotoxins are advancing through clinical trials for various cancers.
Area of Science:
- Biotechnology
- Oncology
- Immunology
Background:
- Pseudomonas exotoxin is a potent toxin with cytotoxic properties.
- Targeting cancer cells specifically remains a challenge in cancer therapy.
- Genetically engineered toxins can offer targeted cancer treatment strategies.
Purpose of the Study:
- To engineer Pseudomonas exotoxin for targeted cancer cell destruction.
- To develop novel recombinant immunotoxins for cancer therapy.
- To evaluate the potential of antibody-targeted toxins in clinical settings.
Main Methods:
- Genetic modification of Pseudomonas exotoxin by deleting its native cell-binding domain.
- Fusion of the modified exotoxin with Fv fragments of antibodies specific to cancer antigens.
- Development of recombinant immunotoxins targeting breast, colon, and other cancer types.
Main Results:
- Successfully created genetically modified Pseudomonas exotoxin derivatives.
- Developed immunotoxins capable of targeting specific cancer cell types.
- Initiated clinical trials for several recombinant immunotoxin candidates.
Conclusions:
- Genetically engineered Pseudomonas exotoxin shows promise for targeted cancer therapy.
- Recombinant immunotoxins represent a viable strategy for developing novel anti-cancer agents.
- Ongoing clinical trials will further define the efficacy and safety of these targeted toxins.